Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $76.76 (market cap $17.66B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 6.2× Dyne Therapeutics Inc. Common Stock's market cap, and iShares iBoxx $ High Yield Corporate Bond ETF is more actively traded (60,522,261 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 61 Days on average.
| DYN | HYG | |
|---|---|---|
Market Cap | $2.86B | $17.66B |
Volume | 3,341,579 | 60,522,261 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $81.28 |
52-Week Low | $14.60 | $76.81 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HYG trades at $77.09, down 0.26% amid a bearish technical signal with moving averages indicating selling pressure. The ETF shows neutral oscillator readings with mixed RSI signals. Recent corporate actions include dividend payments scheduled for 2026. The broader bond market faces pressure from rising Treasury yields, with the 10-year yield hitting levels not seen since 2007 according to MarketBeat on September 30, 2026.
The outlook remains cautious as high yield corporate bonds face headwinds from rising interest rates and inflationary pressures. Investment opportunities exist for income-focused investors through scheduled dividends, but risks include continued bond market volatility and economic uncertainty. HYG's performance will be closely tied to Federal Reserve policy and corporate credit conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
